Acarix

About

Acarix (Nasdaq Stockholm: ACARIX; U.S. Acarix’s flagship technology, the CADScor® System, is CE marked and FDA De Novo cleared for use in patients presenting with chest pain, shortness of breath and suspected CAD. The system is designed to support clinicians in safely ruling out significant coronary artery disease early in the diagnostic pathway, helping drive better patient outcomes and reduce millions of unnecessary, invasive, and costly downstream procedures. The CADScor System leverages highly sensitive acoustic sensors and advanced computational algorithms to analyze coronary blood flow dynamics at the point of care. With a demonstrated negative predictive value of at least 96 percent, it enables confident clinical decision-making within minutes, without radiation, contrast agents, or stress testing. To date, the CADScor System has been used in more than 48,000 patients. Acarix positions CADScor as a first-line diagnostic aid, particularly well suited for primary care, emergency departments, cardiology and other frontline clinical settings seeking to improve patient outcomes while reducing healthcare system burden. Acarix is publicly listed on Nasdaq Stockholm and is focused on scaling adoption of its technology globally to improve access, efficiency, and quality of cardiovascular care.